Literature DB >> 23703741

Assigning exposure duration to single prescriptions by use of the waiting time distribution.

Anton Pottegård1, Jesper Hallas.   

Abstract

PURPOSE: The purpose of this study is to develop and present a method to calculate which exposure duration should be assigned to single prescriptions for use in databases where information on expected duration is not recorded.
METHODS: We propose a method, based on the waiting time distribution (WTD), which estimates how frequently prevalent users redeem new prescriptions. However, we added two steps to the WTD-approach. First, we excluded incident users, representing noise in the analysis. Second, we calculated the cumulative percentage of users that had presented themselves after a given number of days. Using a cutoff value of 80%, we thus calculated the number of days for the majority of prevalent users to present themselves, that is, the exposure duration that should be assigned to the single prescription. The primary strength of the method is that it can be applied in a standardized fashion and that it does not require information on dosage instructions. The primary weakness of the method is that it is only usable on drugs with predominantly chronic use patterns. The method was tested using four model drugs: bendroflumethiazide, warfarin, levothyroxine, and non-steroidal anti-inflammatory drugs (NSAIDs).
RESULTS: We found exposure period estimates of 92, 86, 69, and 210 days for bendroflumethiazide, levothyroxine, warfarin, and NSAIDs prescriptions, respectively. NSAIDs were found not to comply with the requirements of the method. The calculated number of exposed days was only slightly influenced by the assumptions of the method.
CONCLUSIONS: The method provides a useful approach to generate automated estimates of exposure duration that should be assigned to each prescription.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  drug prescriptions; drug utilization; methods; pharmacoepidemiology; registries

Mesh:

Substances:

Year:  2013        PMID: 23703741     DOI: 10.1002/pds.3459

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  21 in total

1.  Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study.

Authors:  Andrea V Margulis; Jesper Hallas; Anton Pottegård; Nina Sahlertz Kristiansen; Willem Jan Atsma; Billy Franks; Milbhor D'Silva; Cristina Varas-Lorenzo; Susana Perez-Gutthann; Alejandro Arana
Journal:  Eur J Clin Pharmacol       Date:  2017-11-13       Impact factor: 2.953

2.  Long-Term Lithium Use and Risk of Renal and Upper Urinary Tract Cancers.

Authors:  Anton Pottegård; Jesper Hallas; Boye L Jensen; Kirsten Madsen; Søren Friis
Journal:  J Am Soc Nephrol       Date:  2015-05-04       Impact factor: 10.121

3.  Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study.

Authors:  Jonathan Brett; Benjamin Daniels; Emily A Karanges; Nicholas A Buckley; Carl Schneider; Atheer Nassir; Andrew J McLachlan; Sallie-Anne Pearson
Journal:  Br J Clin Pharmacol       Date:  2017-08-16       Impact factor: 4.335

4.  Data Resource Profile: The Danish National Prescription Registry.

Authors:  Anton Pottegård; Sigrun Alba Johannesdottir Schmidt; Helle Wallach-Kildemoes; Henrik Toft Sørensen; Jesper Hallas; Morten Schmidt
Journal:  Int J Epidemiol       Date:  2017-06-01       Impact factor: 7.196

5.  Initiation and continuation of antipsychotic medicines in older people following non-psychiatric hospital admission.

Authors:  Lisa M Kalisch Ellett; Nicole L Pratt; Jemisha Apajee; Elizabeth E Roughead
Journal:  Int J Clin Pharm       Date:  2019-06-25

6.  Measurement error and misclassification in electronic medical records: methods to mitigate bias.

Authors:  Jessica C Young; Mitchell M Conover; Michele Jonsson Funk
Journal:  Curr Epidemiol Rep       Date:  2018-09-10

7.  Natural history of bleeding and characteristics of early bleeders among warfarin initiators - a cohort study in Finland.

Authors:  Maria Rikala; Helena Kastarinen; Pekka Tiittanen; Risto Huupponen; Maarit Jaana Korhonen
Journal:  Clin Epidemiol       Date:  2016-02-05       Impact factor: 4.790

8.  Long-term use of secondary prevention medications for heart failure in Western Australia: a protocol for a population-based cohort study.

Authors:  Xiwen Qin; Tiew-Hwa Katherine Teng; Joseph Hung; Tom Briffa; Frank M Sanfilippo
Journal:  BMJ Open       Date:  2016-11-01       Impact factor: 2.692

9.  The Risk of Hip Fracture Due to Mirtazapine Exposure When Switching Antidepressants or Using Other Antidepressants as Add-On Therapy.

Authors:  Michael J Leach; Nicole L Pratt; Elizabeth E Roughead
Journal:  Drugs Real World Outcomes       Date:  2017-12

10.  Association between use of multiple psychoactive medicines and hospitalization for falls: retrospective analysis of a large healthcare claim database.

Authors:  Nicole L Pratt; Emmae N Ramsay; Lisa M Kalisch Ellett; Tuan A Nguyen; John D Barratt; Elizabeth E Roughead
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.